Follistatin-344 Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What Follistatin-344 Does & How It Works

What It Does , Functional Outcomes

• Removes the biological ceiling on skeletal muscle growth by neutralizing the proteins that limit how much muscle the body can build
• Promotes both larger muscle fibers (hypertrophy) and more muscle fibers (hyperplasia) simultaneously - a combination that distinguishes it from most other anabolic interventions studied in the literature
• Reduces muscle wasting in disease models by neutralizing pro-catabolic signaling from activins independently of myostatin
• Modulates metabolic signaling through activin pathway suppression, with implications for glucose and lipid regulation
• Influences bone formation and tissue repair processes through interactions with BMP (bone morphogenetic protein) family members
• Suppresses FSH (follicle-stimulating hormone) secretion indirectly through activin neutralization, affecting reproductive hormone signaling

How It Works , Mechanism of Action

Myostatin Neutralization - Removing the Muscle Growth Limiter (Evidence: Animal - Strong)

Myostatin is a protein produced by muscle tissue that functions as a biological governor on muscle growth - its job is to prevent muscles from getting too large. Follistatin-344 physically encircles myostatin molecules before they can reach their target receptors on muscle cell surfaces. Those receptors are called activin type II receptors (ActRIIB) - think of them as the docking ports myostatin needs to deliver its growth-limiting message. With myostatin physically captured, it cannot deliver that signal. The downstream result is enhanced proliferation and differentiation of myoblasts - the precursor cells that build muscle - along with activation of satellite cells, the muscle stem cells responsible for both fiber growth and new fiber generation.

Activin A and B Sequestration - Anti-Catabolic Signaling (Evidence: Animal and in vitro - Moderate)

Activins are a separate family of proteins that also drive muscle breakdown. FS-344 binds them with an affinity of approximately 45 picomolar - one of the tightest natural protein-protein interactions characterized in the literature. By capturing activin A and activin B, FS-344 reduces muscle protein degradation pathways that activins normally activate through ActRIIB receptors. This is a distinct mechanism from myostatin neutralization, operating through the same receptor family but targeting different upstream proteins. Activin neutralization also indirectly suppresses FSH secretion from the pituitary, because activin normally stimulates FSH synthesis and removing that stimulus lowers FSH output.

SMAD Pathway Suppression - Silencing the Growth-Limiting Genes (Evidence: Animal - Strong)

By blocking myostatin and activins from reaching their receptors, FS-344 prevents the activation of the SMAD 2/3/4 signaling cascade inside muscle cells. SMAD proteins are molecular messengers that carry signals from the cell surface into the nucleus - the cell's control center. When this cascade runs normally, a protein complex called the SMAD 2/3/4 transcriptional complex enters the nucleus and switches on genes that suppress muscle growth. FS-344 prevents the cascade from starting at all, so those growth-suppressive genes remain silent.

BMP Family Binding - Additional Targets, Incompletely Characterized (Evidence: In vitro - Preliminary)

Follistatin-344 also binds multiple bone morphogenetic proteins - BMPs 2, 4, 6, 7, 11, and 15 - at variable and generally lower affinities than its myostatin and activin binding. BMPs are a family of proteins involved in bone formation, tissue repair signaling, and certain growth-related pathways. These interactions have implications for bone formation, tissue repair, and some oncogenic (cancer-related) pathways. The primary literature explicitly characterizes these mechanisms as incompletely understood, and they represent both an additional dimension of FS-344's research utility and an area of ongoing safety characterization.

Follistatin-344 Molecular Profile

Structure reference: View on PubChem CID 178101631 - Publishing team: retrieve 2D structure image from this link.

Follistatin-344 Uses & Benefits

Skeletal Muscle Growth Research

The most extensively documented research application for the Follistatin-344 peptide is skeletal muscle biology. Specifically, researchers examine how removing myostatin and activin signaling simultaneously affects muscle mass, fiber composition, and functional performance. Animal model research has produced some of the most dramatic muscle mass findings in the biological literature using follistatin overexpression. Researchers use FS-344 to study the upper limits of muscle hypertrophy and hyperplasia, to compare the relative contributions of myostatin versus activin inhibition, and to establish what happens when both pathways are suppressed concurrently. The evidence base for muscle effects is the strongest of any application area - though it comes primarily from transgenic models and gene therapy delivery rather than synthetic peptide injection. (Evidence: Strong animal/NHP - Lee, S.J. (2007). PLoS One, 2(8), e789.)

Muscle Wasting Disease Research - DMD and Related Conditions

Duchenne Muscular Dystrophy and related muscle wasting conditions represent the primary therapeutic research direction for FS-344, and the scientific rationale is strong. In DMD (a genetic disease that causes progressive muscle loss), elevated myostatin and activin signaling drives muscle deterioration - exactly what FS-344 neutralizes. The mdx mouse model (the standard preclinical DMD model) responded to AAV1-FS-344 gene therapy with improved muscle mass, reduced muscle damage biomarkers, and functional gains in grip strength and motor performance. These benefits appeared even when treatment began after significant disease progression. The findings informed the rationale for advancing to primate studies and eventual clinical investigation. (Evidence: Strong animal - Haidet et al. (2008). PNAS, 105(11), 4318-4322.)

Metabolic Regulation Research

Activin A is involved in metabolic regulation beyond muscle tissue - including glucose homeostasis (the body's blood sugar balance) and lipid metabolism. By neutralizing activin, FS-344 modulates these metabolic pathways as a secondary effect of its primary mechanism. Researchers studying metabolic disease, insulin sensitivity, or body composition changes use FS-344 in models where the muscle-metabolism interaction is relevant. The evidence base here is less developed than the muscle data, but the mechanistic connection through activin biology is well established. (Evidence: Preliminary - mechanistic basis documented; specific metabolic studies limited in available literature)

Fibrosis Research

Activin A is a recognized pro-fibrotic signaling molecule - meaning it drives the deposition of scar tissue in response to injury or chronic inflammation across multiple tissue types. Follistatin-344's activin neutralization presents a potential research tool for fibrotic disease models, where reducing activin activity may limit pathological scarring. This application is in earlier stages relative to the muscle work, and the relevant evidence comes primarily from the mechanistic understanding of activin biology rather than direct FS-344 fibrosis studies. (Evidence: Preliminary - mechanistic basis established; direct fibrosis studies limited)

Bone and Tissue Repair Research

FS-344's binding to GDF-11 (growth differentiation factor 11, a protein involved in bone development) and multiple BMP family members opens research applications in bone formation, mineralization, and tissue repair. These interactions occur at lower affinities than the myostatin and activin binding, and the downstream effects are less completely characterized. Researchers studying skeletal biology, fracture repair, or multi-tissue regenerative processes may incorporate FS-344 to examine how TGF-beta superfamily modulation affects bone alongside muscle. (Evidence: Preliminary - in vitro; Cash et al. (2012). Journal of Biological Chemistry, 287(2), 1043-1053.)

Where This Follistatin-344 Guide Comes From

Follistatin-344 Results & Timelines

The timeline picture for Follistatin-344 requires a different framing than most compounds in this library. The bulk of documented outcome data comes from animal studies using gene therapy delivery - a mechanism that generates sustained, weeks-long biological effects from a single dose. For synthetic peptide administration, no controlled human timeline data exists in the published literature. The timelines below describe what the animal and NHP research documented, with honest acknowledgment of what this does and does not tell us about synthetic peptide use.

Muscle Mass and Composition Changes - Gene Therapy Animal Model Context

• Weeks 1-4: Initial increases in serum follistatin measurable; early changes in muscle fiber composition beginning in gene therapy studies
• Weeks 4-8: Progressive muscle mass increases documented in mdx mouse models; functional improvements in grip strength beginning to emerge
• Weeks 8-24: Sustained muscle mass enhancement across multiple muscle groups in both wild-type and dystrophic animals; continued reduction in creatine kinase (a blood marker of muscle damage)
• Beyond 24 weeks: Single-dose AAV1-FS-344 sustained muscle effects for over two years in animal models; NHP studies documented 15-20% muscle size gains at 60-week endpoints

Muscle Wasting Disease Model Context

• Weeks 1-8: Measurable reduction in serum creatine kinase in dose-dependent fashion; early improvements in functional metrics
• Weeks 8-24: Functional gains in grip strength and motor performance; improvements in muscle mass and reduced pathological features in dystrophic tissue
• Key finding on timing: Benefits were documented even when treatment began in aged mdx mice at 6.5 months - a point representing significant disease progression - suggesting the window for intervention extends beyond early disease stages

How to Administer Follistatin-344

Intramuscular Injection (IM)

Intramuscular injection was the primary delivery route in the gene therapy research that generated FS-344's most compelling data. AAV1-FS-344 vectors were administered intramuscularly to both mdx mice and cynomolgus macaques in the key published studies. For synthetic peptide, IM injection is used in research settings given the compound's size and the desire for absorption into systemic circulation. Direct pharmacokinetic data for this route with synthetic FS-344 in humans has not been published.

Subcutaneous Injection (SubQ)

Subcutaneous injection is documented in research peptide contexts as an alternative administration route for FS-344. No comparative bioavailability data between SubQ and IM for synthetic FS-344 has been published. Given the molecular weight of 3,780 g/mol - substantially larger than most research peptides - absorption dynamics from the SubQ depot may differ meaningfully from smaller compounds. This has not been directly characterized in available literature.

Oral

Oral administration is not viable for Follistatin-344. The compound is a 344-amino acid glycoprotein - the same structural complexity that makes it an effective high-affinity binding protein also makes it completely unable to survive the digestive process intact. Gastric acid and digestive enzymes (proteins that break down food in the stomach) would degrade it before it reaches systemic circulation. No oral formulation or delivery technology has been studied for FS-344 in the available literature.

Follistatin-344 Dosage & Cycle Length

This section requires a different framing than the equivalent section in most peptide guides. For the vast majority of compounds covered in this library, a broad dosing range drawn from published research, practitioner protocols, and community data can be presented as a meaningful starting point. For Follistatin-344, that data simply does not exist in any form that would be responsible to present as a dosing framework.

Here is what is known and what is not.

What the published research used:

The animal studies that established FS-344's muscle biology effects used two delivery mechanisms. Transgenic mouse models expressed elevated follistatin endogenously - a methodology with no direct parallel in human peptide use. The DMD and NHP studies used AAV1-FS-344 gene therapy vectors (laboratory-engineered viral particles that carry a genetic payload into cells) delivered intramuscularly, with dosing tiered across low, medium, and high vector doses. These are gene therapy doses measured in viral particles or infectious units. They are categorically different from dosing a synthetic reconstituted peptide, and the figures have no relevance to synthetic peptide dosing.

What is not established:

No published pharmacokinetic study has characterized the absorption, distribution, half-life, or dose-response relationship of synthetic FS-344 peptide administered subcutaneously or intramuscularly in humans. The 90-130 minute half-life figure referenced in this guide comes from rat models of the FST-315 isoform - the circulating form derived from FS-344, not FS-344 itself. Extrapolating a dosing framework from this number would require assumptions that the available science does not support.

What appears in community documentation:

Dosing figures circulate in research and biohacking communities, but they lack the foundation - verified compound identity, controlled conditions, pharmacokinetic anchoring - that would make them meaningful to present here. Presenting those figures without that foundation risks implying a structure that does not exist.

Cycle length:

Gene therapy studies demonstrated sustained effects for over two years following a single dose in animal models. For synthetic peptide, no cycle length data is established.

Follistatin-344 Vial Sizes, Costs & Quality

Common vial sizes: Follistatin-344 research peptide is most commonly available in 1 mg vials, with some suppliers also offering larger formats. The compound's high molecular weight (3,780 g/mol) relative to other research peptides means that even small quantities represent a significant mass of active material.

Typical cost range: FS-344 is among the most expensive research peptides available at current market pricing. U.S.-manufactured research-grade peptides in the 1 mg range typically fall in the $150-$300 per vial range, with significant variation based on purity specification, supplier, and availability. This pricing reflects the genuine synthesis complexity of producing a 344-amino acid glycoprotein to research grade - it is not a compound where low pricing is a sign of competitive efficiency.

Storage - lyophilized (dry powder):

• Temperature: -20 degrees C for long-term storage
• Shelf life: Stable at -20 degrees C; avoid repeated freeze-thaw cycles
• Light sensitivity: Protect from light

Storage - reconstituted (in solution):

• Temperature: 2-8 degrees C (standard refrigeration)
• Use window: Use promptly after reconstitution; discard unused solution per standard research protocols for high-value peptides

Normal appearance after reconstitution: FS-344 is water soluble and typically dissolves into a clear to slightly opalescent solution. Some degree of slight opacity can be normal for a large glycoprotein at research concentrations - this does not necessarily indicate degradation.

Signs of degradation: Visible particulates or chunks that do not dissolve on gentle swirling, significant discoloration beyond a slight tint, or unusual odor are indicators that the peptide may be degraded or contaminated. A peptide of this cost and complexity that shows degradation signs should not be used in research.

Quality Considerations

Follistatin-344 is one of the most synthesis-intensive compounds in the research peptide space. It is a 344-amino acid glycoprotein with an unusually high cysteine content and multiple disulfide bonds - and those disulfide bonds have to form correctly. If they do not, the compound will have the right molecular weight and still be essentially non-functional. Its binding activity depends entirely on the three-dimensional structure those bonds maintain. A supplier pricing FS-344 at a fraction of the market norm is not finding efficiencies - something in the synthesis, purification, or testing chain has been cut. For a compound this structurally complex, quality verification means HPLC purity testing (a laboratory method that separates and measures compound components) and identity confirmation, not just a label claim. USA-manufactured research-grade FS-344 comes with documented manufacturing standards, third-party testing, certificates of analysis with purity and identity data, and full chain of custody from synthesis to delivery - the baseline any serious research application requires.

Follistatin-344 Side Effects & Safety

Follistatin-344's safety profile in the published literature reflects its research-stage status. The animal and NHP studies that established its efficacy did not report significant adverse events in the available source material, and the preclinical tolerability data is generally favorable in the contexts studied. The more important safety picture for this compound comes from mechanistic analysis - what FS-344 does biologically across multiple systems, and what the implications of those effects might be.

Side Effect Spectrum

Contraindications

• Active or history of malignancy: BMP pathway interactions and potentially oncogenic pathway modulation create theoretical concerns in cancer contexts; the implications are not characterized in available literature
• Reproductive health conditions or fertility concerns: Activin neutralization suppresses FSH signaling through the pituitary; individuals with conditions dependent on normal activin-FSH axis function should approach with caution - though FS-344's lower affinity for reproductive tissues relative to the FS-288 isoform may partially mitigate this risk
• Cardiovascular disease: Myostatin and activin are expressed in cardiac tissue; systemic suppression of these pathways carries theoretical implications for cardiac biology that have not been directly studied in available literature
• Growing subjects (skeletal development incomplete): GDF-11 antagonism and BMP pathway modulation have theoretical implications for ongoing skeletal development; insufficient data to characterize safety in this population

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data; use is not recommended without medical supervision
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• Individuals on hormonal therapies or fertility treatment: FSH modulation through activin neutralization may interact with hormone-based therapeutic protocols; consultation with a qualified healthcare provider is warranted

Red Flags , Stop Use and Seek Medical Attention If:

• Unusual or rapid changes in cardiac rhythm, chest discomfort, or unexplained shortness of breath
• Sudden hormonal changes, including unexpected changes in reproductive function or menstrual irregularity
• Unusual skeletal pain, joint discomfort, or rapid changes in bone-related symptoms
• Any systemic inflammatory response - fever, widespread swelling, rash - not consistent with routine injection site reaction

Drug and Compound Interactions

No drug interactions with synthetic FS-344 peptide have been formally studied or documented in the available published literature. Theoretical interaction considerations exist based on mechanism. Compounds that influence the TGF-beta superfamily, myostatin pathway, or activin signaling - including other myostatin inhibitors, IGF-1, and anabolic compounds that affect muscle tissue signaling - may have additive or potentially unpredictable combined effects given FS-344's broad multi-target binding profile. The synergy with IGF-1 has been proposed in review literature as a theoretically meaningful combination for anabolic applications, but this has not been studied in controlled contexts. No interactions with common pharmaceutical medications are documented.

Follistatin-344 Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability

Direct pharmacokinetic data for synthetic FS-344 peptide administered by injection in humans does not exist in the published literature. The available data comes from animal models and gene therapy contexts. In AAV1-FS-344 gene therapy studies, serum follistatin levels increased substantially in treated animal models, with expression from the transduced muscle cells providing sustained circulating levels. This delivery mechanism - where the body's own transduced cells become the production source - generates fundamentally different pharmacokinetics than injecting a pre-formed synthetic peptide.

Distribution

In vivo, FS-344 is processed after synthesis into the FST-315 isoform (a shorter, 315-amino acid form that becomes the primary version circulating in the bloodstream). The FST-315 isoform has reduced heparin-binding affinity compared to the FS-288 isoform. Heparin is a molecule found on cell surfaces; lower affinity for it means FST-315 circulates more freely rather than being held in tissues. Follistatin generally does not cross the blood-brain barrier at significant levels based on current understanding, though this has not been directly studied for FS-344 specifically.

Half-Life

The reported half-life of 90-130 minutes comes from rat models using the native FST-315 isoform. This data should not be directly applied to synthetic FS-344 peptide administration in humans - the isoform, species, and delivery context are all different from what would characterize synthetic peptide use. This is a significant data gap.

Metabolism & Elimination

As a glycoprotein, FS-344 is expected to be broken down through standard protein degradation pathways - enzymes cleave the molecule into its component amino acids, which are then recycled by the body. The sugar molecules attached to the protein (glycosylation) influence its metabolic stability compared to unmodified peptides, though the specific metabolic fate of synthetic FS-344 has not been characterized in the literature.

The pharmacokinetic data gap is one of the most significant research limitations for this compound. Dosing frequency, optimal timing, and duration of effect following synthetic peptide administration cannot be derived from the available literature.

Mechanistic Research

Myostatin Neutralization Through High-Affinity Binding (Evidence: Animal - Strong; Lee, S.J. (2007). PLoS One, 2(8), e789.)

The Lee (2007) study examined what happens when follistatin overexpression is combined with myostatin knockout in mice - two separate interventions that each increase muscle mass independently. The combined condition produced quadruple the muscle mass of normal controls, significantly exceeding what either intervention achieved alone. This finding established that follistatin operates through pathways beyond myostatin neutralization. Eliminating myostatin entirely and also blocking it with follistatin produced additive effects rather than redundant ones - which means follistatin must be doing something else on top of blocking myostatin.

Isoform-Specific Binding Selectivity (Evidence: Human and animal - Moderate; Schneyer et al. (2004). Journal of Clinical Endocrinology & Metabolism, 89(10), 5067-5075.)

Schneyer et al. (2004) characterized the differential binding properties of the FST-315 and FS-288 isoforms. They found that FST-315 - generated from FS-344 - has 10-fold lower affinity for activin compared to FS-288. This reduced affinity particularly affects interaction with ovarian tissue receptors, where FS-288 is preferentially held. The practical research significance is that FS-344-derived FST-315 may exert systemic muscle effects while producing fewer reproductive tissue side effects compared to FS-288-based interventions. This property informed its selection for muscle-targeted gene therapy approaches.

BMP Pathway Interactions (Evidence: In vitro - Preliminary; Cash et al. (2012). Journal of Biological Chemistry, 287(2), 1043-1053.)

Cash et al. (2012) characterized FS-344's interactions with multiple BMP family members, finding binding at variable and generally lower affinities than the myostatin and activin interactions. BMPs 2, 4, 6, 7, 11, and 15 were among the characterized binding partners. The functional implications span bone formation, tissue repair signaling, and certain oncogenic pathways. The authors explicitly noted that these mechanisms require further investigation to characterize fully.

Dual Inhibition of Myostatin and Activin (Evidence: Animal - Moderate; Castonguay et al. (2019). Journal of Pharmacology and Experimental Therapeutics, 368(3), 435-445.)

Castonguay et al. (2019) examined the relative contributions of myostatin versus activin inhibition to muscle preservation outcomes. The research suggested that dual inhibition of both pathways provides superior muscle mass maintenance compared to targeting myostatin alone, particularly in disease states characterized by ongoing muscle catabolism. This finding reinforces the mechanistic significance of FS-344's multi-target binding profile - addressing two independent catabolic drivers rather than one.

Condition-Focused Research

Skeletal Muscle Hypertrophy and Hyperplasia {#research-muscle}

Transgenic mouse models expressing elevated follistatin demonstrated 194-327% increases in muscle mass compared to wild-type controls. Concurrent increases in both fiber number (66% hyperplasia) and fiber diameter (28% hypertrophy) were observed across multiple muscle groups including quadriceps, tibialis anterior, gastrocnemius, and triceps. This combination of both hypertrophy and hyperplasia is mechanistically notable. Most anabolic interventions primarily drive hypertrophy rather than generating new fibers, making the dual effect a distinguishing characteristic of follistatin-level pathway modulation. (Evidence: Animal - Strong; Lee, S.J. (2007). PLoS One, 2(8), e789.)

Duchenne Muscular Dystrophy Models {#research-dmd}

Haidet et al. (2008) administered AAV1-FS-344 to mdx mice at tiered doses. Treated animals showed improved muscle mass, reduced pathological features in dystrophic muscle tissue, improved grip strength and motor performance, and dose-dependent reduction in serum creatine kinase. Critically, these benefits were observed even when treatment began in animals aged 6.5 months, representing significant disease progression. In a separate component of the same study, a single AAV1-FS-344 dose produced sustained muscle mass enhancement for over two years in both wild-type and dystrophic mice. (Evidence: Animal - Strong; Haidet et al. (2008). PNAS, 105(11), 4318-4322.)

Nonhuman Primate Muscle Response {#research-nhp}

Cynomolgus macaque (nonhuman primate) studies using AAV1-FS-344 gene transfer demonstrated 15-20% increases in muscle size over the study period, with studies running to 60 weeks. Fast-twitch fiber (Type II, the fibers responsible for power and sprint-type output) hypertrophy was specifically noted. The NHP data represents the closest preclinical approximation to human response available for FS-344. The muscle size increases - substantially smaller in magnitude than the transgenic mouse findings - represent meaningful gains in a species much closer to human physiology. This data supported advancement toward human clinical investigation. (Evidence: Nonhuman primate - Moderate)

Safety & Tolerability Research

In the published animal studies, FS-344 administered via AAV1 gene therapy vectors was tolerated in both mdx mice and cynomolgus macaques over extended study periods. The mdx mouse studies ran to multiple time points across the disease course; the NHP studies ran to 60 weeks. No specific toxicity events are reported in the available source material from these studies. Creatine kinase levels decreased rather than increased in treated mdx mice, suggesting reduced ongoing muscle damage rather than treatment-induced injury. Long-term single-dose studies demonstrated sustained effects for over two years without reported safety signals. The notable absence of toxicity reporting should be interpreted alongside the study designs: controlled animal studies focus primarily on efficacy outcomes, and the safety data for synthetic peptide administration in humans remains entirely absent from the published literature.

Research Limitations

The most significant limitation specific to Follistatin-344 is the gap between delivery mechanism and research compound form. The studies generating the most compelling data used gene therapy vector delivery - a mechanism that produces weeks to years of endogenous follistatin expression - not synthetic peptide injection. The pharmacokinetics, dose-response relationships, and efficacy data from gene therapy studies cannot be directly applied to synthetic peptide use. No published human pharmacokinetic study characterizes synthetic FS-344 absorption, half-life, or dose-response by any injection route. The available half-life data (90-130 minutes) comes from rat models of the FST-315 isoform and represents a different isoform from a different species via a different delivery context. BMP interaction mechanisms are explicitly characterized as incompletely understood in the primary literature. The oncogenic and cardiovascular implications of systemic TGF-beta superfamily suppression have not been studied at the duration or depth needed to characterize long-term safety.

Is Follistatin-344 Legal? Regulatory & Sports Status

FDA status: Follistatin-344 is not FDA-approved for any therapeutic indication as of July 2026. It is classified as a research compound and sold under research-use-only designation. It is not available through licensed compounding pharmacies for human use.

Research Use Only: In most jurisdictions, FS-344 is classified as a research compound not approved for human use. This designation reflects the current state of clinical development - the compound has not completed the regulatory pathway required for therapeutic approval in any indication, and no Investigational New Drug application for synthetic peptide administration has been publicly reported. The gene therapy vector AAV1-FS-344 has been investigated in preclinical settings as a potential therapeutic approach to DMD, but this is a distinct regulatory track from the research peptide form.

WADA / USADA status: Follistatin-344 is explicitly prohibited by the World Anti-Doping Agency under Section S4.4 of the WADA Prohibited List - "Agents preventing activin receptor IIB activation" (ActRIIB is the cell surface receptor that myostatin and activins must engage to deliver their muscle-limiting signals). This prohibition applies both in-competition and out-of-competition for all athletes subject to the WADA Code. USADA applies the WADA Prohibited List for U.S. athletes in WADA-governed sports.

Country-specific notes: Regulatory classification for research compounds varies by jurisdiction. FS-344's classification as a research peptide does not guarantee legal status for import, possession, or use in every country. Users and researchers are responsible for verifying applicable regulations in their specific location.

Detection: Source material does not detail specific detection methodologies or validated detection windows for FS-344. The half-life of 90-130 minutes (for the FST-315 circulating form in rats) suggests relatively rapid clearance of the native form, though detection windows for prohibited substance testing are typically designed around metabolites and biomarkers rather than the parent compound alone. Gene therapy delivery of AAV1-FS-344 would present substantially different and substantially longer detection challenges compared to synthetic peptide administration.

Follistatin-344 vs. Alternatives

Commonly Paired With , Synergistic Stacks

• FS-344 + IGF-1: The combination of follistatin-based disinhibition and IGF-1's active anabolic signaling has been proposed in review literature as potentially synergistic - removing the growth ceiling while simultaneously providing an anabolic stimulus. This synergy has been proposed theoretically but has not been studied in controlled research. Combining two compounds with significant independent effects on muscle physiology and with incompletely characterized safety profiles represents a research context requiring careful design.
• FS-344 + Cytokine Antagonists: In inflammatory disease or muscle wasting models, pairing FS-344's activin neutralization with targeted cytokine antagonists has been proposed as a complementary approach. Each compound would address a different component of the catabolic environment. This combination is entirely speculative with no controlled supporting data - it exists at the theoretical stage only.
• FS-344 + Myostatin Propeptide: For researchers specifically examining the relative contributions of myostatin versus activin inhibition, pairing FS-344 with a more selective myostatin inhibitor allows for comparison of pathway-specific effects against broader TGF-beta superfamily suppression. This is a research design rationale rather than a documented synergistic protocol.

Stacking information is for educational context - individualized research protocol design is outside the scope of this guide.

Alternatives , When Another Compound May Be Considered

Myostatin Propeptide (MSTN Propeptide) The myostatin propeptide is the natural inhibitory partner of mature myostatin - the body produces it to regulate myostatin activity. As a more narrowly targeted myostatin inhibitor compared to FS-344, it offers a more selective intervention without the broad TGF-beta superfamily binding that characterizes FS-344. Researchers specifically interested in myostatin biology without the activin, BMP, and GDF-11 modulation that FS-344 introduces may prefer this more targeted approach. Evidence is limited relative to follistatin, with fewer published studies across rodent and primate models.

ACE-031 (Soluble ActRIIB) ACE-031 is a fusion protein that acts as a decoy receptor for ActRIIB, capturing multiple TGF-beta family ligands including myostatin and activins - similar in scope to FS-344's multi-target binding. It reached Phase I/II clinical trials for Duchenne Muscular Dystrophy before development was halted due to adverse events including nosebleeds and telangiectasias (small dilated blood vessels visible in the skin). The ACE-031 adverse event history is an important reference point for understanding the potential risks of broad TGF-beta superfamily suppression at the systemic level. ACE-031 is not currently available as a research compound.

BMP-7 (Bone Morphogenetic Protein 7) For researchers specifically interested in the bone development and tissue repair aspects of TGF-beta superfamily biology rather than muscle applications, BMP-7 represents a distinct research direction - a BMP family member rather than an inhibitor of the family. The comparison is context-dependent: FS-344 modulates BMP-7 availability through binding, while exogenous BMP-7 acts as a direct agonist for bone and tissue repair pathways.

Comparison table (include when 3 or more alternatives are meaningful):

Build Your Follistatin-344 Protocol

FAQs

What is Follistatin-344?

Follistatin-344 is a synthetic analogue of a naturally occurring human protein that neutralizes multiple members of the TGF-beta superfamily - including myostatin, activin A, activin B, and GDF-11. The "344" in its name refers to the amino acid count of the full-length precursor molecule it replicates. It is classified as an autocrine glycoprotein and is researched primarily for its effects on skeletal muscle biology, muscle wasting diseases, and related metabolic and fibrotic pathways.

What does Follistatin-344 do?

Follistatin-344 removes the biological ceiling on muscle growth by neutralizing myostatin and activin - proteins that normally limit how much skeletal muscle the body can build and maintain. In animal models, this has produced dramatic increases in muscle mass through both increased fiber size and increased fiber number simultaneously. Beyond muscle, FS-344 modulates metabolic, fibrotic, bone development, and reproductive signaling pathways through its additional TGF-beta family binding activity.

How long does Follistatin-344 take to work?

The animal research that documented FS-344's effects used gene therapy delivery, where muscle mass changes developed over weeks to months following a single dose. For synthetic peptide administration, no human pharmacokinetic or outcome timeline data exists in the published literature. Community reports in the research context vary widely and cannot be anchored to standardized dosing or verified compound identity, making a reliable onset estimate impossible to provide with confidence.

What is the typical dose of Follistatin-344?

No validated human dosing protocol exists for synthetic Follistatin-344. The published research data comes primarily from gene therapy vector studies in animal models - a delivery mechanism that is categorically different from synthetic peptide injection, and those figures have no direct relevance to synthetic peptide dosing. Dosing figures circulate in research communities, but they lack the pharmacokinetic foundation that would make them meaningful as a protocol starting point.

Is Follistatin-344 legal?

Follistatin-344 is not FDA-approved for human use and is classified as a research compound in most jurisdictions. For competitive athletes, it is explicitly prohibited by WADA under Section S4.4 of the Prohibited List ("Agents preventing activin receptor IIB activation"), both in-competition and out-of-competition. Regulatory status varies by country - users and researchers are responsible for understanding the rules in their specific location.

Can Follistatin-344 be taken orally?

No. Follistatin-344 is a 344-amino acid glycoprotein that would be broken down by gastric acid and digestive enzymes before reaching systemic circulation. This is not a compound-specific limitation - it applies to essentially all proteins and peptides of this size and complexity. The structural features that make FS-344 an effective high-affinity binding protein are the same features that make it unable to survive the digestive process intact.

How is Follistatin-344 different from Follistatin-315?

Follistatin-344 is the full-length precursor molecule - 344 amino acids - that the body converts into Follistatin-315 through post-translational processing (chemical modifications made to the protein after it is built). FST-315, with 315 amino acids, is the primary form that circulates in the bloodstream. It has reduced heparin-binding affinity compared to the FS-288 tissue-bound variant, meaning it circulates more freely. The synthetic research compound FS-344 replicates the precursor structure, and its in vivo conversion into FST-315 is part of what generates the circulating activity documented in animal studies.

Why was Follistatin-344 chosen for muscular dystrophy research specifically?

Several factors made FS-344 a logical candidate for DMD research. Its isoform selectivity - the FST-315 derived from FS-344 has 10-fold lower affinity for reproductive tissues than FS-288 - reduced concerns about off-target reproductive effects. Its dual neutralization of both myostatin and activins addresses two independent drivers of muscle wasting rather than one. And the preclinical data in mdx mice showed benefits even when treatment began after significant disease progression, which is critical for diseases like DMD where diagnosis typically follows established muscle loss.

Does Follistatin-344 affect hormones beyond muscle?

Yes, and this is an important consideration. Activin normally stimulates FSH (follicle-stimulating hormone) secretion from the pituitary gland, so FS-344's activin neutralization can suppress FSH levels. The FST-315 isoform generated from FS-344 has reduced affinity for ovarian tissues specifically, which partially limits this effect compared to other follistatin variants - but FSH suppression is a documented mechanism worth understanding before working with this compound. Beyond FSH, FS-344's broad TGF-beta family binding means it influences signaling across muscle, bone, liver, reproductive, and potentially cardiac tissues simultaneously.

Final Thoughts on Follistatin-344

Follistatin-344 occupies a unique position in the research peptide landscape. It has some of the most striking preclinical findings in muscle biology research and a clear mechanistic rationale grounded in well-characterized molecular interactions. It also has one of the most significant gaps between the documented research evidence and what is known about its effects in humans via synthetic peptide administration. The animal data is real. The 194-327% muscle mass increases in transgenic mouse models, the functional improvements in DMD models even at late disease stages, the 15-20% primate muscle gains - these findings come from rigorous published research and represent genuinely meaningful science. What they are not is a direct template for human use.

The honest picture is one of a research compound at an earlier stage of human characterization than its prominence in performance communities might suggest. No validated human dosing protocol, no published human pharmacokinetic data for the synthetic peptide form, and a broad mechanism of action that intersects with reproductive, cardiovascular, bone, and potentially oncogenic pathways - all of which remain incompletely characterized at the safety level. The WADA prohibition reflects the recognized performance-enhancing potential. The research limitations in this guide reflect an honest accounting of what the science has and has not established. Both things are true simultaneously.

For anyone tracking developments in muscle wasting disease research, follistatin biology, or TGF-beta superfamily modulation more broadly, FS-344 will remain an important compound to follow. The preclinical rationale for its therapeutic applications in DMD and related conditions is among the strongest in the gene therapy literature, and the science continues to develop. MyPeptidePal tracks emerging protocol data on this compound and will continue updating as the human evidence base evolves.

References

1. Lee, S.J. (2007). Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One, 2(8), e789.

2. Haidet, A. M., Rizo, L., Handy, C., Umapathi, P., Eagle, A., Shilling, C., Boue, D., Martin, P. T., Sahenk, Z., Mendell, J. R., & Kaspar, B. K. (2008). Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proceedings of the National Academy of Sciences, 105(11), 4318-4322.

3. Schneyer, A., Schoen, A., Quigg, A., & Sidis, Y. (2004). Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG). Journal of Clinical Endocrinology & Metabolism, 89(10), 5067-5075.

4. Cash, J. N., Rejon, C. A., McPherron, A. C., Bernard, D. J., & Thompson, T. B. (2012). The structure of myostatin:follistatin 288: Insights into receptor utilization and heparin binding. Journal of Biological Chemistry, 287(2), 1043-1053.

5. Castonguay, R., Lachey, J., Wallner, S., Strand, J., Liharska, K., Watanabe, A. E., Cannell, M., Davies, M. V., Sako, D., Troy, M. E., Krishnan, L., Mulivor, A. W., Li, H., Keates, S., Alexander, M. J., Pearsall, S., Kumar, R., & Grinberg, A. V. (2019). Follistatin-288-Fc fusion protein promotes localized growth of skeletal muscle. Journal of Pharmacology and Experimental Therapeutics, 368(3), 435-445.